Berry Group’s GSK GSK Stock Holding History

Berry Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,614	Closed	-$212K	–	110
2019 Q4	$212K	Buy	+3,614	New	+$201K	0.11%	121

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Berry Group's GSK Position: Q1 2020 in Review

Berry Group sold out of GSK (GSK) in Q1 2020, closing a stake of 3,614 shares — an estimated $212K sold.

Berry Group first reported a position in GSK in Q4 2019 and held it in 1 quarter. The position peaked at $212K in Q4 2019. 817 funds tracked by Wall St. Rank hold GSK as of Q1 2020.

Berry Group reported no remaining GSK position as of Q1 2020 after selling out during the quarter.
Berry Group sold 3,614 GSK shares in Q1 2020, an estimated $212K.
Berry Group first reported a position in GSK in Q4 2019 and held it in 1 quarter.
Berry Group's GSK position peaked at $212K in Q4 2019.
817 funds tracked by Wall St. Rank held GSK as of Q1 2020.

Based on Berry Group's 13F filing for Q1 2020, filed 11 May 2020.